APA aipamena

Buscombe, J., Gillett, D., Bird, N., Powell, A., Heard, S., & Aloj, L. (2020). Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases. World J Nucl Med.

Chicago Style aipamena

Buscombe, John, Daniel Gillett, Nick Bird, Anne Powell, Sarah Heard, and Luigi Aloj. "Quantifying the Survival Benefit of Completing All the Six Cycles of Radium-223 Therapy in Patients With Castrate-resistant Prostate Cancer With Predominant Bone Metastases." World J Nucl Med 2020.

MLA aipamena

Buscombe, John, et al. "Quantifying the Survival Benefit of Completing All the Six Cycles of Radium-223 Therapy in Patients With Castrate-resistant Prostate Cancer With Predominant Bone Metastases." World J Nucl Med 2020.